These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28860883)

  • 41. Exploring the presence of narcolepsy in patients with schizophrenia.
    Sansa G; Gavaldà A; Gaig C; Monreal J; Ercilla G; Casamitjana R; Ribera G; Iranzo A; Santamaria J
    BMC Psychiatry; 2016 Jun; 16():177. PubMed ID: 27245445
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multiple treatment comparison in narcolepsy: a network meta-analysis.
    Lehert P; Falissard B
    Sleep; 2018 Dec; 41(12):. PubMed ID: 30239930
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sodium Oxybate Treatment in Pediatric Type 1 Narcolepsy.
    Moresco M; Pizza F; Antelmi E; Plazzi G
    Curr Drug Metab; 2018; 19(13):1073-1079. PubMed ID: 29512449
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of Taiwan's 2021 COVID-19 lockdown on the symptom severity and quality of life of patients with narcolepsy.
    Chin WC; Huang YS; Tang I; Lee PY; Wang CH; Chao KY
    Sleep Biol Rhythms; 2023 Oct; 21(4):419–429. PubMed ID: 37363640
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy.
    Black J; Pardi D; Hornfeldt CS; Inhaber N
    Sleep Med; 2009 Sep; 10(8):829-35. PubMed ID: 19616998
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sodium oxybate: a review of its use in the management of narcolepsy.
    Robinson DM; Keating GM
    CNS Drugs; 2007; 21(4):337-54. PubMed ID: 17381187
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sodium oxybate improves excessive daytime sleepiness in narcolepsy.
    Black J; Houghton WC
    Sleep; 2006 Jul; 29(7):939-46. PubMed ID: 16895262
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized trial evaluating the effectiveness of sodium oxybate therapy on quality of life in narcolepsy.
    Weaver TE; Cuellar N
    Sleep; 2006 Sep; 29(9):1189-94. PubMed ID: 17040006
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures.
    Scrima L; Hartman PG; Johnson FH; Hiller FC
    Biol Psychiatry; 1989 Aug; 26(4):331-43. PubMed ID: 2669980
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness.
    Inocente C; Arnulf I; Bastuji H; Thibault-Stoll A; Raoux A; Reimão R; Lin JS; Franco P
    Clin Neuropharmacol; 2012; 35(2):55-60. PubMed ID: 22356925
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiovascular fitness in narcolepsy is inversely related to sleepiness and the number of cataplexy episodes.
    Matoulek M; Tuka V; Fialová M; Nevšímalová S; Šonka K
    Sleep Med; 2017 Jun; 34():7-12. PubMed ID: 28522101
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antidepressant drugs for narcolepsy.
    Vignatelli L; D'Alessandro R; Candelise L
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003724. PubMed ID: 16034909
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical, behavioural and polysomnographic correlates of cataplexy in patients with narcolepsy/cataplexy.
    Mattarozzi K; Bellucci C; Campi C; Cipolli C; Ferri R; Franceschini C; Mazzetti M; Russo PM; Vandi S; Vignatelli L; Plazzi G
    Sleep Med; 2008 May; 9(4):425-33. PubMed ID: 17681883
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy.
    Romigi A; Vitrani G; Lo Giudice T; Centonze D; Franco V
    Drug Des Devel Ther; 2018; 12():2665-2675. PubMed ID: 30214155
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In-field assessment of sodium oxybate effect in pediatric type 1 narcolepsy: an actigraphic study.
    Filardi M; Pizza F; Antelmi E; Ferri R; Natale V; Plazzi G
    Sleep; 2018 Jun; 41(6):. PubMed ID: 29522206
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correlation between the Epworth Sleepiness Scale and the Maintenance of Wakefulness Test in patients with narcolepsy participating in two clinical trials of sodium oxybate.
    Erman M; Emsellem H; Black J; Mori F; Mayer G
    Sleep Med; 2017 Oct; 38():92-95. PubMed ID: 29031763
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Physical Activity and Sleep/Wake Behavior, Anthropometric, and Metabolic Profile in Pediatric Narcolepsy Type 1.
    Filardi M; Pizza F; Antelmi E; Pillastrini P; Natale V; Plazzi G
    Front Neurol; 2018; 9():707. PubMed ID: 30197622
    [No Abstract]   [Full Text] [Related]  

  • 58. Sodium oxybate: efficacy, safety and tolerability in the treatment of narcolepsy with or without cataplexy.
    Owen RT
    Drugs Today (Barc); 2008 Mar; 44(3):197-204. PubMed ID: 18536781
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hypocretin (orexin) deficiency predicts severe objective excessive daytime sleepiness in narcolepsy with cataplexy.
    Baumann CR; Khatami R; Werth E; Bassetti CL
    J Neurol Neurosurg Psychiatry; 2006 Mar; 77(3):402-4. PubMed ID: 16484654
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of Excessive Daytime Sleepiness in Narcolepsy With Baclofen.
    Morse AM; Kelly-Pieper K; Kothare SV
    Pediatr Neurol; 2019 Apr; 93():39-42. PubMed ID: 30595352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.